Federal Ruling on Mifepristone Mail Delivery Impacts Abortion Access

A federal judge in the U.S. has denied a request from Louisiana officials to halt the mail delivery of mifepristone nationwide, amidst an ongoing legal case. The case remains paused, with the judge mandating the Food and Drug Administration (FDA) to provide an update within six months as part of its regulatory compliance review of the drug.

Louisiana Attorney General Liz Murrill aimed to suspend FDA regulations that permit mifepristone to be ordered online and shipped via mail. Although the judge did not support the request, there is potential for revisiting the matter based on the FDA's progress in its review. "Should the agency fail to complete its review... the Court’s analysis... will inevitably change," the judge noted. Murrill plans to appeal, citing potential harm to Louisiana, where abortion is prohibited throughout pregnancy.

Abortion rights organizations responded to the ruling's implications, emphasizing that it is not conclusive. Alexis McGill Johnson, President and CEO of Planned Parenthood Federation of America, highlighted ongoing nationwide scrutiny of mifepristone and abortion access. Following the 2022 Supreme Court decision allowing states to impose abortion bans, the use of telehealth services surged, with telehealth accounting for one in four abortions by late 2024. A 2025 study showed women in states with abortion prohibitions often obtained pills via mail, raising concerns about potential risks associated with mailing abortion pills.